ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Precigen Inc

Precigen Inc (PGEN)

1.45
0.05
(3.57%)
Closed March 27 04:00PM
1.45
0.00
( 0.00% )
Pre Market: 04:12AM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

PGEN News

Official News Only

PGEN Discussion

View Posts
Monksdream Monksdream 2 weeks ago
PGEN under $2
πŸ‘οΈ0
glenn1919 glenn1919 3 weeks ago
PGEN..............................https://stockcharts.com/h-sc/ui?s=PGEN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 4 weeks ago
PGEN......................................https://stockcharts.com/h-sc/ui?s=PGEN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
PGEN under $2
πŸ‘οΈ0
webbie01 webbie01 6 months ago
Owing this stock is like chinese water torture drip, drip, drip,
down 5%, down 5%, down 5%
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
I think they were looking to generate interest in the ''platform.'' The company is another chameleon that has fooled many investors over the years with no real progress. They stay listed just to do (unlimited) cash grabs. The SP has slumped time and time again, with RJ Kirk screwing many!
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
PGEN under $2
πŸ‘οΈ0
Investor_Advocate Investor_Advocate 7 months ago
Precigen (ex Intrexon XON) recently agreed to pay $13M to the former shareholders to settle the misleading statements lawsuit.

Court: Northern District of California
Case number: 5:20-cv-06936-BLF
Case details and filing for compensation here.
πŸ‘οΈ0
AJ Freely AJ Freely 8 months ago
$PGEN - 👆 Up 12% Pre-Market/Current Price $1.33
👉Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
👉And provides Financial Results and updates
πŸ‘οΈ0
TJG TJG 9 months ago
Looks like the interest and volume is picking up on this PR today
https://finance.yahoo.com/news/precigen-receives-breakthrough-therapy-designation-113000335.html
πŸ‘οΈ0
Paullee Paullee 10 months ago
new seeking alpha story
https://seekingalpha.com/article/4609689-unraveling-the-promise-of-precigen-biotech-innovations-amid-financial-challenges?mailingid=31704118&messageid=2800&serial=31704118.1838&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=31704118.1838
πŸ‘οΈ0
NY1972 NY1972 11 months ago
This target must be older than 1/2 USA population
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
Of all the targets they chose mesothelin! https://www.prnewswire.com/news-releases/precigen-presents-preclinical-data-for-the-next-generation-mesothelin-ultracar-t-with-intrinsic-pd-1-blockade-at-the-aacr-annual-meeting-2023-301798470.html
πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
It makes little sense for them to waste resources on CD19 and BCMA-targeted CAR-T's considering just how crowded each space is. As for IL-12, it failed in multiple indications https://www.prnewswire.com/news-releases/precigen-regains-exclusive-rights-to-proven-car-t-targets-cd19-and-bcma-to-enable-unencumbered-development-and-commercialization-of-ultracar-t-301788820.html
πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
LYEL has an anti-ROR1 CAR-T in the clinic, but only in solid tumours (starting in NSCLC and TNBC) https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6 https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4

They are also working on a next-gen version https://lyell.com/pdf/SITC_NR4A3%20Poster_Print_102022_FINAL.pdf https://lyell.com/pdf/SITC_STIM-R%20Poster_ePoster_FINAL.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
Wow, just over 17 months since they filed an IND! https://www.prnewswire.com/news-releases/precigen-announces-further-advancement-of-ultracar-t-platform-with-first-patient-dosed-in-phase-11b-dose-escalationdose-expansion-study-of-prgn-3007-in-advanced-ror1-hematological-and-solid-tumors-301784205.html
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
More preclinical data! https://www.abstractsonline.com/pp8/#!/10828/presentation/3388

Considering the other (preclinical) data for PRGN-3005, 3006 and 3007, I wouldn't read much, if anything into it. Also, by now, you would think that the company would have translational data from the two ongoing trials, which could help inform them as to why genes they might silence next, using (from memory) miRNA.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
JPM presentation https://investors.precigen.com/static-files/bd82c7b7-e8b9-4b19-be44-6a9de4165ae6

Some quick thoughts.

Slide 4: Despite AG019 being listed they did not provide an update.

Slide 8: The internal assessment leaves a lot to be desired. Focusing on iPSC-derived, it allows for a company to create multiplexed engineered, clonal master cell lines, which are a renewable source that enables routine, mass production of immune cells that are off-the-shelf (on-demand availability). Also, allows for broad patient access as it can scale. For example, FATE created over 300 doses of FT500 for around $3,000 per dose. PGEN on the other hand has never disclosed any (projected) COGM.

As for auto, GILD's Kite has a median manufacturing time (from apheresis to finished product) of 16 days in the US, but are hoping to reduce this to just a few days. BMY and others are following suit. For COGM (one paper puts it in the $160-170,000 range), it could be cut in at least half with automation alone.

Slide 11: Talk about apples to oranges! Not only do they compare auto to allo (both iPSC- and donor-derived), but CAR-T to CAR-NK as well! Typically, NK do not expand upon encounter with antigen and have (very) limited persistence.

Slide 12: If the depth and duration of response (from the dose expansion) is as poor as it has been no more time and money should be wasted on it.

Slide 15: Again, they have switched to giving the therapy via IV (plus LD chemo), so there is no known safety (on target, off tumour toxicities, CRS and/or ICANS) or efficacy profile. Also, the ORR (when given via IP) was zero. In addition, those treated at DL3 did worse (despite better expansion and persistence) than those treated at DL1 and DL2.

Slide 17: True, gene therapies have the potential to revolutionise medicine, but I very much doubt any company will be using the AdenoVerse platform to deliver them.

Slide 24: Totality of the data is what matters, not a single patient. I hope the update for PRGN-2012 isn't like the last time!

Slide 27: The ORR for the vaccine alone was zero. As for the combo, 30%, but just three out of ten. Based on that, they shouldn't have continued with the current trial.

Slide 29: Major milestones? The only updates for this year will be PRGN-2012 and PRGN-2009 (+/- M7824).
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
So, out of six milestones for this year, the company failed to accomplish (at least) four of them. I say at least four as I'm not 100% certain that a multicentre expansion cohort to test PRGN-3006 for R/R AML happened.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
PRGN-3005: They moved forward with testing DL3 plus LD chemo prior to IV infusion. Also, are able to incorporate repeat dosing. Based on the previous data, as well as this, I don't hold out much hope.

PRGN-3006: Another year has passed and only nine additional patients have been treated. Worse still, none have responded.

PRGN-3007: Not only haven't they dosed the first patient, but the trial isn't even listed on the clinicaltrials website.
πŸ‘οΈ0
Rubraquercus Rubraquercus 2 years ago
The cash runway is now much longer with the sale of transova and a $100 million shelf with Cantor Fitz. Sadly, hell-in flat lied in the recent conf call about raising money, and then 24hrs later we get the shelf, unreal.

<<Jennifer Kim with Cantor Fitzgerald. Please go ahead.

Hey, everyone.... And then my second question is broader, with the Trans Ova divestiture, has anything changed in your mind in terms of portfolio prioritization and added flexibility to explore opportunities that you weren't able necessarily to consider beforehand?


Answer; As Harry mentioned, we have a solid runway well to the fourth quarter of 2023, which has allowed us to basically go through our – some of the clinical timelines that we have for reporting the data. And I think that's going to be very good. And we basically do not have to take anything from the financial strength that we have, or I should say the money that we have, currently that is dedicated to our clinical trial and be diverting this for our convertible notes. And that's – obviously it's a huge, I think, pressure off at this point, especially during this financial times and not diluting our investor base. So we are very happy about that.

We have prioritized portfolio as we have mentioned in our slides and according to the three pillar of a strategy that we have and we mentioned for instance, even in regard to our AG019, which is a very exciting program for a type 1 diabetes, we feel that this has served best with partnership, which the discussions on our partnerships are ongoing and we look forward to report on that in the near future.>>
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
''Meanwhile, Precigen faces a different type of problem: a $201m convertible debt comes due for repayment in July 2023, but the group has just $142m in cash, and its market cap has fallen to $260m.

With little chance of an equity raise at the current valuation and in the current market Precigen has mooted selling off non-core assets to raise the necessary cash. Wells Fargo analysts suggest that Precigen’s lead Actobiotics asset, AG019 for type 1 diabetes, could be the first to go.

The company could also try to renegotiate the debt, but equity investors seldom come out well from such moves.'' https://www.evaluate.com/vantage/articles/news/deals/ataras-latest-setback-troubled-field
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Thanks. I had issues with the target for PGEN-3006, as back during an ISCT '17 presentation, Dr. Saar Gill suggested that just hitting CD123, or CD33 in AML was a non-starter, and smarter approach needed. Based on that and the comments from the PI, I think the company should discontinue the program.

πŸ‘οΈ0
Rubraquercus Rubraquercus 2 years ago
Great post, wow, nice reflection of the reality, sad as it may be...
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
AG019: Doesn't work as well as some think, and would require much larger PhIIb (and possibly PhIII) trials. Resources the company probably doesn't have.

PRGN-3005: It has taken 2-2.5+ years to enrol not even half a dozen patients, with efficacy being very minimal (I'm being generous!). No patients have been enrolled in the IV arm (that I'm aware of).

PRGN-3006: While encouraging (in those that got the therapy with LD chemo), only a small number have been treated, and now the PI says it could be a bridge to a transplant.

PRGN-3007: The first patient hasn't been dosed. Also, it will face competition from the likes next-gen versions, such as LYEL's.

INXN-4001: Looks dead.

PRGN-2009: Mono is likely dead as not a single patient responded. As for the combo, too early to say, but the former should say it all.

PRGN-2012: Looks to me like they are trying to cherry-pick the best responses, as they didn't disclose the data from the others treated to date.

Finally, mbIL-15 isn't working as expected, and going forward, it seems they won't be giving the CAR-T's without LD chemo as they once hoped. Also, there is talk about redosing!
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
The PI has said it could be a bridge to a transplant.
πŸ‘οΈ0
Oxonius Oxonius 2 years ago
A reminder of the GenVec days:

Researchers Look to Reverse Hearing Loss With Regenerative Hair Therapy

Over 5% of the world’s population is affected by disabling hearing loss, a condition that is largely irreversible. One biotech company, Frequency Therapeutics, has set out to change that. The company’s scientists have found a way to help hair cells in the ear regenerate, in turn increasing a patient’s ability to hear. β€œ[Hearing] connects people to their community and cultivates a sense of identity,” said one of the founders, Jeff Karp. β€œI think the potential to restore hearing will have enormous impact on society.”

So far, they have treated more than 200 patients during three clinical trials and are gearing up for another one with 124 people. Karp said he hopes this innovation will eventually make reversing hearing loss a simple, fast, and accessible procedure. Co-founder Robert Langer added: β€œSome of these people [in the trials] couldn’t hear for 30 years, and for the first time they said they could go into a crowded restaurant and hear what their children were saying. It’s so meaningful to them.”
πŸ‘οΈ0
gator16 gator16 2 years ago
PGEN Drug Fast Tracked !! WHOOPPEEE !!
πŸ‘οΈ0
gator16 gator16 2 years ago
Wells Fargo placed an overweight on PGEN this week with a $17.00 Target Price per share
πŸ‘οΈ0
gator16 gator16 2 years ago
Not to my knowledge but who knows ! They do a lot of stuff all the time. Kirk love him or hate him is a pretty smart guy !
πŸ‘οΈ0
noode12 noode12 2 years ago
Is there any truth that pgen it looking to buyout rgbp(regene bio pharma) just for there patents that they have??
πŸ‘οΈ0
gator16 gator16 2 years ago

PGEN Analyst Research NASDAQ
PGEN Analyst Ratings
Consensus Strong Buy

Based on 3 analysts offering recommendations for pgen in the last 3 months.
Analyst Firms Making Recommendations

H C WAINWRIGHT
JP MORGAN SECUR
STIFEL NICOLAUS

Analyst
$11.5

Based on analysts offering 12 month price targets for PGEN in the last 3 months. The average price target is $11.5 with a high estimate of $13 and a low estimate of $10. Sign in to your SmartPortfolio to see more analyst recommendations.
πŸ‘οΈ0
gator16 gator16 2 years ago
I am a buyer !
I have seen enough to know it is a good time to buy (for me) !!
Now own 100000 shares
πŸ‘οΈ0
gator16 gator16 2 years ago
Kirk bought 1000000 shares this week !!
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
She runnin again
πŸ‘οΈ0
make it happen make it happen 3 years ago
A long way to go clinical studies are far from done...
πŸ‘οΈ0
make it happen make it happen 3 years ago
Negative triple digit percent profitability, high negative returns in all aspects, revenue per share $0.56 cents, huge debt over $184,000,000 and cash flow is negative $100,000,000. Hemorrhaging everything.

Profitability
Profit Margin -134.74%
Operating Margin (ttm) -89.28%

Management Effectiveness
Return on Assets (ttm) -13.45%
Return on Equity (ttm) -79.97%

Income Statement
Revenue (ttm) 97.85M
Revenue Per Share (ttm) 0.56
Quarterly Revenue Growth (yoy) -17.90%
EBITDA -72.59M
Net Income Avi to Common (ttm) -104.77M

Balance Sheet
Total Cash (mrq) 105.69M
Total Cash Per Share (mrq) 0.51
Total Debt (mrq) 184.12M
Total Debt/Equity (mrq) 105.33
Current Ratio (mrq) 5.71
Book Value Per Share (mrq) N/A

Cash Flow Statement
Operating Cash Flow (ttm) -65.66M
Levered Free Cash Flow (ttm) -34.93M
πŸ‘οΈ0
jgrabar jgrabar 3 years ago
https://grabarlaw.com/the-latest/precigen-inc-investigation/
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Welcome!
πŸ‘οΈ0
nealhugh nealhugh 3 years ago
IN at $8.3942
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
More coverage...now stifel @13.
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Slow claps...bout time.
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
$14 target from Wells Fargo
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Coverage initiated by Wells Fargo...time for takeoff soon. They did the offering. They want more $$ for the shares ;)
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Coverage initiated by B Riley yesterday with a target of $10. They must have shares from the offering. Pump it up baby
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Look at evfm! That mofo has been running for a while now. That one took months for me to make $$.
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Follow the $$
πŸ‘οΈ0
Porterhouse10 Porterhouse10 3 years ago
Wheewf, not sure about that bloated pig, but GLTY!
πŸ‘οΈ0
Planopenny Planopenny 3 years ago
Got some bids in at sndl
πŸ‘οΈ0
Porterhouse10 Porterhouse10 3 years ago
PYRNF sorry, Cathy been buying that, but missed it
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock